Price (90d)
$262.19Signal Score (90d)
50Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $12.69B | $499.00M | $12.20 |
| 2024 | $12.71B | $489.00M | $11.29 |
| 2023 | $11.98B | $406.00M | $9.20 |
| 2022 | $12.46B | $867.00M | $17.40 |
| 2021 | $9.92B | $519.00M | $9.94 |
Social Signal Score
Earnings
Thu, Oct 22(in 2 months)
Consensus estimate $4.17 per share
Typical surprise +1.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$3.73 vs $3.69beat
- Thu, Apr 23$2.54 vs $2.27beat
- Wed, Feb 11$3.59 vs $3.66miss
- Thu, Oct 23$3.57 vs $3.56beat
- Thu, Jul 24$3.32 vs $3.11beat
- Wed, Apr 23$2.46 vs $2.40beat
Estimates and results for R via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from R's reported EPS growth of 5.3% a year over 4 years.
- EPS in 5 years
- $15.45
- Implied price
- $247.28
- Return from $263.96
- -1.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $122.94 — -53.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -4.7% | -15.7% | -13.0% | -10.7% | -8.5% | -6.6% |
| 0.3% | -11.2% | -8.5% | -6.0% | -3.7% | -1.7% |
| 5.3% | -6.8% | -3.9% | -1.3% | 1.1% | 3.2% |
| 10.3% | -2.4% | 0.7% | 3.4% | 5.9% | 8.1% |
| 15.3% | 2.0% | 5.2% | 8.1% | 10.7% | 13.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (5)
- Newsaccessnewswire.com·2d ago·Neutral
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform Collaboration with one of the world's largest animal health companies expected to accelerate TRUFORMA adoption, expand installed base, and drive recurring diagnostic revenue in Canada ANN ARBOR, MI / ACCESS Newswire / August 13, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering…
View source ↗ - News (RSS)seekingalpha·3d ago·Positive
Ryder System, Inc. (R) Presents at Deutsche Bank's Chicago Industrials Summit Transcript
View source ↗ - Newsseekingalpha.com·3d ago·Positive
Ryder System, Inc. (R) Presents at Deutsche Bank's Chicago Industrials Summit Transcript Ryder System, Inc. (R) Presents at Deutsche Bank's Chicago Industrials Summit Transcript
View source ↗ - Newsnewsfilecorp.com·4d ago·Neutral
Theralase(R) Announces $5 Million Brokered LIFE Offering Toronto, Ontario--(Newsfile Corp. - August 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "
View source ↗ - Newsnewsfilecorp.com·7d ago·Neutral
Theralase(R) Grants Stock Options Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, announces the grant of stock options. The Company has granted an aggregate of 7,000,000 stock options to eligible participants pursua
View source ↗